Latest news with #Perimeter
Yahoo
03-07-2025
- Business
- Yahoo
Morgan Stanley Highlights Stability and Growth at Perimeter Solutions (PRM)
Perimeter Solutions Inc. (NYSE:PRM) is one of the 20 undervalued momentum stocks that are taking off. In a recent note, Morgan Stanley analyst Daniel Kutz reiterated his Buy rating on Perimeter Solutions (PRM), with a price target of $17. His positive stance on the stock is grounded in both the strength of the company's core business and its disciplined M&A strategy. A key focus is Perimeter's U.S. Retardants segment, which Kutz expects to draw increased investor interest as wildfire season approaches. Unlike many cyclical businesses, this unit is relatively less affected by broader economic fluctuations, offering a degree of earnings stability even if macro conditions soften. This makes the business particularly valuable in a more uncertain economic environment. thanmano/ Kutz also highlights that Perimeter has been targeting assets with recurring revenues, strong cash flow generation, and long-term growth potential, which are key qualities that support sustainable performance. The analyst also cited the recent bolt-on acquisition in the Printed Circuit Board product line, which he believed reinforces confidence in the company's ability to build value through mergers and acquisitions. With solid cash reserves, Perimeter appears well-equipped to continue adding to its portfolio in a strategic and accretive way. According to Kutz, all the factors outlined above combine to support his bullish view on the stock. Perimeter Solutions Inc. (NYSE:PRM) provides solutions for the Fire Safety and Specialty Products industries. While we acknowledge the potential of PRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 10 Best Tech Stocks to Buy According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
02-07-2025
- Business
- Cision Canada
Medical City Dallas Hospital Adopts Perimeter's Innovative OCT Imaging Technology for Surgery
Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries TORONTO and DALLAS, July 2, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced today that Medical City Dallas Hospital, an award-winning 899-bed acute care hospital in the Dallas-Fort Worth area, has adopted the company's current S-Series OCT (optical coherence tomography) technology for high-resolution visualization of tissue microstructures during surgery. The move comes on the heels of the hospital's participation in the pivotal, randomized controlled trial of Perimeter's next-generation B-Series device, which combines proprietary artificial intelligence ("AI") technology with OCT, and is being evaluated by the U.S. Food and Drug Administration for use during breast-conserving surgeries in the United States. "We are incredibly proud to partner with Medical City Dallas Hospital and its team of surgeons, who are truly innovators in their field," said Perimeter CEO Adrian Mendes. "Working with Dr. DiPasquale and Dr. Anderson and the Medical City Dallas team, who used our B-Series in the randomized controlled pivotal trial, has been invaluable to advancing our next-generation product and we are pleased that they are adopting our commercially approved S-Series to potentially enhance margin visualization in the OR." Medical City Dallas Hospital is the latest U.S. hospital to adopt the S-Series OCT, as Perimeter continues to deploy the technology nationwide. Cleared by the U.S. Food and Drug Administration (FDA) in 2021 for a general tissue indication, S-Series OCT is a high-resolution technology that, unlike X-ray, magnetic resonance imaging (MRI), or ultrasound, can 'see' disease at the cellular level. It is optimized down to 2mm for identifying regions of interest in tissue microstructures, and features such as blood vessels, ducts, and glands, making it ideal for visualizing surgical margins. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. S-Series OCT Intended Use and Unapproved Uses The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image review manipulation software for identifying and annotating regions of interest. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, statements regarding the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date; use of proceeds from the Offering; fees anticipated to be paid to the Agent and terms thereof; regulatory and exchange approvals, including the listing of the common shares offered pursuant to the Offering on the TSXV, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Annual Information Form for the year ended December 31, 2024, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Contacts Stephen Kilmer Investor Relations Direct: 647-872-4849 Email: [email protected] Susan Thomas Media Relations Direct: 619-540-9195 Email: [email protected] Adrian Mendes Chief Executive Officer Toll-free: 888-988-7465 (PINK) Email: [email protected] SOURCE Perimeter Medical Imaging AI Inc.
CTV News
14-06-2025
- Business
- CTV News
Costco onto next step to build new Manitoba store
FILE - A lone shopper pushes a cart toward the entrance of a Costco warehouse, March 13, 2025, in Sheridan, Colo. (AP Photo/David Zalubowski, File) Costco has cleared a hurdle in its bid to build another Manitoba location. Public hearings were held at the RM of West St. Paul's council meeting Thursday night for two variance applications associated with the potential new store. One is a conditional use application for a proposed auto service station and a garden centre, and the other is a separate variance application to reduce required loading space. Mayor Peter Truijen told CTV News feedback at the public hearings was largely positive, and council voted unanimously on both applications. 'A lot of people think this is a good thing,' he said. Next, the wholesaler will need to submit a development agreement to council, the mayor explained, which would also require a vote. The proposed 161,992-square-foot store would be built on Meadowland Drive. Truijen believes the store will attract Manitobans from a number of communities. 'It's right on the Perimeter. It's pretty easy access for a lot of residents, not just West St. Paul, but Selkirk, St. Clements—lots of places north of the city.'
Yahoo
10-06-2025
- Business
- Yahoo
Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th
TORONTO and DALLAS, June 10, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time. A live stream of the presentation will be available here and on the Investors section of Perimeter's website, where it will also be archived for approximately 90 days. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the outcomes of the clinical trial and future submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. CONTACTS: Stephen KilmerInvestor RelationsDirect: 647-872-4849Email: skilmer@ Adrian MendesChief Executive OfficerToll-free: 888-988-7465 (PINK)Email: investors@ View original content to download multimedia: SOURCE Perimeter Medical Imaging AI Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
10-06-2025
- Business
- Cision Canada
Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th
TORONTO and DALLAS, June 10, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time. A live stream of the presentation will be available here and on the Investors section of Perimeter's website, where it will also be archived for approximately 90 days. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the outcomes of the clinical trial and future submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Stephen Kilmer Investor Relations Direct: 647-872-4849 Email: [email protected] Adrian Mendes Chief Executive Officer Toll-free: 888-988-7465 (PINK) Email: [email protected]
